1. Home
  2. BWXT vs RGEN Comparison

BWXT vs RGEN Comparison

Compare BWXT & RGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • BWXT
  • RGEN
  • Stock Information
  • Founded
  • BWXT 1867
  • RGEN 1981
  • Country
  • BWXT United States
  • RGEN United States
  • Employees
  • BWXT N/A
  • RGEN N/A
  • Industry
  • BWXT
  • RGEN Medical/Dental Instruments
  • Sector
  • BWXT
  • RGEN Health Care
  • Exchange
  • BWXT Nasdaq
  • RGEN Nasdaq
  • Market Cap
  • BWXT 10.2B
  • RGEN 7.6B
  • IPO Year
  • BWXT N/A
  • RGEN N/A
  • Fundamental
  • Price
  • BWXT $117.16
  • RGEN $156.55
  • Analyst Decision
  • BWXT Strong Buy
  • RGEN Buy
  • Analyst Count
  • BWXT 9
  • RGEN 12
  • Target Price
  • BWXT $126.50
  • RGEN $187.44
  • AVG Volume (30 Days)
  • BWXT 789.5K
  • RGEN 470.1K
  • Earning Date
  • BWXT 02-25-2025
  • RGEN 02-19-2025
  • Dividend Yield
  • BWXT 0.82%
  • RGEN N/A
  • EPS Growth
  • BWXT 24.26
  • RGEN N/A
  • EPS
  • BWXT 3.02
  • RGEN N/A
  • Revenue
  • BWXT $2,682,902,000.00
  • RGEN $633,513,000.00
  • Revenue This Year
  • BWXT $9.56
  • RGEN $2.28
  • Revenue Next Year
  • BWXT $6.29
  • RGEN $9.88
  • P/E Ratio
  • BWXT $38.78
  • RGEN N/A
  • Revenue Growth
  • BWXT 12.02
  • RGEN N/A
  • 52 Week Low
  • BWXT $78.47
  • RGEN $113.50
  • 52 Week High
  • BWXT $136.31
  • RGEN $211.13
  • Technical
  • Relative Strength Index (RSI)
  • BWXT 50.72
  • RGEN 60.07
  • Support Level
  • BWXT $111.16
  • RGEN $149.15
  • Resistance Level
  • BWXT $115.45
  • RGEN $160.64
  • Average True Range (ATR)
  • BWXT 2.81
  • RGEN 5.96
  • MACD
  • BWXT 0.72
  • RGEN 0.91
  • Stochastic Oscillator
  • BWXT 69.52
  • RGEN 79.57

About BWXT BWX Technologies Inc.

BWX Technologies Inc is a specialty manufacturer & service provider of nuclear components. It operates in two segments. The government Operations segment consists of legacy Nuclear Operations Group & Nuclear Services Group segments with certain research & development activities in the areas of advanced reactors & advanced manufacturing. The commercial Operations segment consists of the legacy Nuclear Power Group segment with certain research and development & commercialization activities in the areas of medical & industrial radioisotopes & radiopharmaceuticals. The majority is from the Government Operations segment. Geographically, it operates in the United States, Canada & United Kingdom, out of which the majority is from the United States.

About RGEN Repligen Corporation

Repligen, headquartered in Waltham, Massachusetts, is a global life sciences company that develops and sells bioprocessing equipment and supplies used in the manufacturing of biologic drugs, including monoclonal antibodies, recombinant proteins, vaccines, and cell and gene therapies. Its customers include biopharmaceutical companies, contract development and manufacturing organizations, or CDMOs, and other life science companies. It sells four main product categories: filtration (including fluid management) is the largest category and was 54% of 2023 revenue, while chromatography, proteins, and process analytics were 20%, 16%, and 9%, respectively. Customers in North America, Europe, and Asia Pacific contributed 44%, 37%, and 19% of revenue, respectively.

Share on Social Networks: